Treatment for Mycoplasma genitalium
For confirmed M. genitalium infection, treat with azithromycin 1 g orally as a single dose, as this regimen demonstrates superior efficacy compared to doxycycline for this specific pathogen 1.
Critical Context: Outdated Guidelines vs. Current Reality
The provided guidelines are from 2010 and predate the widespread recognition of macrolide resistance in M. genitalium. While these guidelines correctly identify that M. genitalium "responds better to azithromycin" than doxycycline 1, they do not address the antimicrobial resistance crisis that now defines M. genitalium management.
Current Best Practice (Based on Contemporary Evidence)
First-Line Treatment Algorithm
For uncomplicated M. genitalium infection:
If macrolide resistance testing is available:
If resistance testing is unavailable (most U.S. settings):
Why the 2010 Guidelines Are Insufficient
The single-dose azithromycin 1 g regimen recommended in the 2010 CDC guidelines 1 is now problematic because:
- Macrolide resistance exceeds 50% in many populations 4
- Single-dose azithromycin has directly contributed to widespread resistance development 5
- Extended azithromycin regimens (5 days) have higher cure rates than single-dose 2, 5
For Complicated Infections
Pelvic inflammatory disease or epididymitis: Moxifloxacin 400 mg once daily for 14 days (not 7) 2, 5
Second and Third-Line Options
If first-line treatment fails:
- Second-line: Moxifloxacin 400 mg daily for 7-10 days 2
- Third-line options:
Key Predictors of Treatment Failure
High-risk features requiring more aggressive initial therapy:
- Chlamydia trachomatis co-infection (strongest predictor, 3.2-fold increased failure risk) 6
- Male sex 6
- Previous treatment failure
- Known macrolide resistance
Sequential doxycycline-quinolone therapy demonstrates superior long-term effectiveness with faster clearance (median 7 vs. 10 weeks) and lower recurrence rates compared to azithromycin monotherapy 6.
Critical Management Points
Testing Recommendations
- Test only symptomatic patients: urethritis, cervicitis, proctitis, PID 3
- Test sexual contacts of confirmed cases 3
- Do NOT test asymptomatic patients (including pregnant women without exposure history) 3
- Macrolide resistance testing is recommended but not widely available in the U.S. 3
Sexual Activity Restrictions
- Abstain from sexual intercourse for 7 days after single-dose therapy or until completion of multi-day regimens AND symptom resolution 1
- Abstain until all sexual partners are treated 1
Partner Management
- All sexual partners within the preceding 60 days must be evaluated and treated 1
- Partners should receive empiric treatment effective against both chlamydia and M. genitalium
Follow-Up
- Test of cure is NOT routinely recommended for asymptomatic patients who completed treatment 2, 3
- Re-evaluate only if symptoms persist or recur 1
- Consider testing for other STIs including HIV and syphilis 1
Common Pitfalls to Avoid
- Using single-dose azithromycin 1 g: This drives resistance and has suboptimal cure rates
- Treating asymptomatic patients without known exposure: Leads to unnecessary antibiotic use and resistance
- Failing to treat sexual partners: High reinfection rates
- Using doxycycline monotherapy: Only 30-40% cure rate 2, 5
- Not considering co-infections: CT co-infection dramatically increases failure risk 6
The Resistance Crisis
Current resistance patterns:
- >50% macrolide resistance in many populations 4
- Increasing fluoroquinolone resistance 4, 2
- Dual-class resistance emerging 7
This reality necessitates a paradigm shift toward risk-stratified initial therapy prioritizing sequential regimens (doxycycline followed by moxifloxacin) for high-risk patients, particularly those with CT co-infection or male sex 6.